

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955  
• Email: contact@alkem.com • Website: www.alkemlabs.com  
• CIN: L00305MH1973PLC174201

29<sup>th</sup> May, 2024

To,

<b>The Corporate Relationship Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <b>Scrip Code: 539523</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <b>Scrip Symbol: ALKEM</b>
---	--

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”): Re-appointment of Directors**

Dear Sir(s)/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 29<sup>th</sup> May, 2024 has *inter alia*:

1. based on recommendation of Nomination and Remuneration Committee, Audit Committee and subject to the approval of shareholders at the ensuing Annual General Meeting, approved the re-appointment of Mr. Basudeo N. Singh as an Executive Chairman of the Company for a term of 3 (three) consecutive years with effect from 01<sup>st</sup> April, 2025 upto 31<sup>st</sup> March, 2028.
2. based on recommendation of Nomination and Remuneration Committee, Audit Committee and subject to the approval of shareholders at the ensuing Annual General Meeting, approved the re-appointment of Mr. Sarvesh Singh as an Executive Director of the Company for the term of 5 (five) consecutive years with effect from 11<sup>th</sup> November, 2024 upto 10<sup>th</sup> November, 2029.
3. based on recommendation of Nomination and Remuneration Committee and subject to the approval of shareholders at the ensuing Annual General Meeting, approved the re-appointment of Mr. Narendra Kumar Aneja as an Independent Director of the Company for the second term of 5 (five) consecutive years with effect from 16<sup>th</sup> March, 2025 upto 15<sup>th</sup> March, 2030.

Further, the details required to be disclosed as per SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are provided as Annexure-A below.

Kindly take the same on your records.

Sincerely,  
For **Alkem Laboratories Limited**

**Manish Narang**  
**President - Legal, Company Secretary & Compliance Officer**

Encl: a/a



## ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955  
• Email: contact@alkem.com • Website: www.alkemlabs.com  
• CIN: L00305MH1973PLC174201

### Annexure A

Sr. No.	Particulars	Details		
1.	Name	<b>Mr. Basudeo N. Singh</b>	<b>Mr. Sarvesh Singh</b>	<b>Mr. Narendra Kumar Aneja</b>
2.	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Re-appointment of Mr. Basudeo N. Singh as an Executive Chairman of the Company.	Re-appointment of Mr. Sarvesh Singh as an Executive Director of the Company.	Re-appointment of Mr. Narendra Kumar Aneja for second term as an Independent Director of the Company.
3.	Date of <del>appointment/ re-appointment/ cessation</del> (as applicable) and term of <del>appointment/ reappointment</del>	<p><b>Date of Re-appointment:</b> 01<sup>st</sup> April, 2025</p> <p><b>Term of Re-appointment:</b> 3 (three) consecutive years with effect from 01<sup>st</sup> April, 2025 upto 31<sup>st</sup> March, 2028.</p>	<p><b>Date of Re-appointment:</b> 11<sup>th</sup> November, 2024</p> <p><b>Term of Re-appointment:</b> 5 (five) consecutive years with effect from 11<sup>th</sup> November, 2024 upto 10<sup>th</sup> November, 2029.</p>	<p><b>Date of Re-appointment:</b> 16<sup>th</sup> March, 2025</p> <p><b>Term of Re-appointment:</b> 5 (five) consecutive years with effect from 16<sup>th</sup> March, 2025 upto 15<sup>th</sup> March, 2030.</p>
4.	Brief Profile	NA	NA	NA
5.	Disclosure of relationships between directors	NA	NA	NA